S&P 500 7543.64 +0.81%
NASDAQ 26206.89 +1.30%
TASI 10808.43 -0.42%
Oil (WTI) 72.18 +0.14%
Oil (Brent) 76.56 +0.34%
VIX 15.78 -0.38%
Gold 4110.20 -0.74%
USD/SAR 3.75 +0.00%

CRISPR Therapeutics AG

CRSP · Healthcare · · USD
56.34 USD
0.00 (-4.83%)
● Updated 2026-07-10 15:40 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score HOLD Mid-term (Position)

60
/ 100
Technical 75
Trend & RS 52
Momentum 58
Fundamental 33
Macro 78
Liquidity 39
ComponentScoreWeight
Technical 75.0 20%
Trend & RS 52.5 30%
Momentum 57.9 15%
Fundamental 33.3 10%
Macro 78.4 20%
Liquidity 39.0 5%

Trade Setup

Entry 56.34
Stop Loss 49.62 (11.9%)
Target 1 (1:1) 63.06 (+11.9%)
Target 2 (2:1) 69.78 (+23.9%)
ATR(14) 3.36 (6.0%)
Risk per Share 6.72
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 73.8 +0.95
Momentum 57.9 +0.32
Quality 40.0 -0.40
Composite 57.2

Quality Scores

Piotroski F-Score 3 /9 — Weak
✗ ✗ ✗ ✗ ✓ ✓ ✗ ✗ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio N/A 22.0 Inline
P/B Ratio 3.0 4.0 Below

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Position Sizing — Kelly Criterion

4.8%
Recommended Size
39.71%
Full Kelly
19.85%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 60/100. Estimated win rate 58%, avg win 8.6%, avg loss 3.8%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
52.67
RSI(14)
1.7518
MACD

Relative Strength (RS) WEAK RS

31
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY → FLAT (-2.6% vs SPY 3M)
RS vs Sector INLINE (Healthcare)
RS New High No (3d since high)
Sector Outperformance -0.6% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
WEAK RS: Underperformer — the stock is lagging the market. Avoid until RS trend reverses upward.

Technical Indicators

IndicatorValueSignal
Rsi 52.67 NEUTRAL
Macd 1.7518 BULLISH
Ma Cross 53.26 / 55.53 DEATH CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.85x NORMAL

Key Levels

LevelPrice
52-Week High78.48
Bollinger Upper61.84
SMA(200)55.53
SMA(50)53.26
SMA(20)54.84
Current Price56.34
Bollinger Lower47.85
52-Week Low44.12
ATR(14)3.36

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

ACCUMULATION E Confidence
50%
Acc: 1.0  |  Dist: 1.0  |  Markup: 0.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-07-02 Normal 1.73x Normal bar — no special VSA pattern
2026-07-06 Normal 1.21x Normal bar — no special VSA pattern
2026-07-07 Normal 0.98x Normal bar — no special VSA pattern
2026-07-08 Normal 0.72x Normal bar — no special VSA pattern
2026-07-09 Normal 0.85x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 58.38 Above Kijun
Kijun-sen (26) 56.23 Base line
Senkou A 57.31 Leading span A
Senkou B 55.19 Leading span B
Cloud 55.19 – 57.31 Bullish (Green)
Price vs Cloud 56.34 Inside Cloud
Chikou Span 52.02 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 47.85 – 61.84  |  KC: 50.09 – 59.6

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Regular Bearish RSI 24

Anchored VWAP

VWAP: 53.28 Anchor: 2026-03-30 (52w Low) ABOVE AVWAP +5.7%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/CRSP

Valuation

MetricValue
Market Cap5.55B
P/E (TTM)N/A
Forward P/EN/A
P/B2.99
EPS-5.87

Financial Health

MetricValue
Revenue Growth68.6%
Profit MarginN/A
ROE-31.2%
Debt/Equity43.41
Current Ratio17.96
Dividend YieldN/A
Payout RatioN/A
Beta1.70

Trading Data

56.34
Open
56.34
Day High
56.34
Day Low
1.43M
Volume (0.8x avg)

Recent News (8)

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Zacks · 2026-07-09
Vertex’s Crinetics Deal Balances Growth with Integration Risk
MarketBeat · 2026-07-08
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside
Trefis · 2026-07-08
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Motley Fool · 2026-07-08
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
Zacks · 2026-07-07
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
Motley Fool · 2026-07-07
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
Motley Fool · 2026-07-07
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 2026-07-06

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —